{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-002898","form_type":"8-K","ticker":"AIMD","cik":"0001014763","company_name":"Ainos, Inc.","filed_at":"2024-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.105036+00:00","generated_at":"2026-06-05T00:21:07.652271+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ainos reports FY2023 revenue drop to $122K; net loss $13.8M","bullets":["Revenue fell 97% to $122,112 from $3.52M in 2022, driven by COVID-19 test kit sales decline.","Gross loss of $253,733 vs positive gross profit of $1.4M a year earlier; net loss $13.77M vs $14.01M.","Cash and cash equivalents $1.89M at Dec 31, 2023, nearly flat from $1.85M at Dec 31, 2022.","R&D expenses rose to $7.32M; SG&A fell to $5.64M on lower share-based compensation.","Strategic pivot: advancing VELDONA Phase III, AI Nose VOC platform with NISD & Inabata, and pet supplement sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-002898","json":"https://secwatch.observer/filing/0001654954-24-002898.json","markdown":"https://secwatch.observer/filing/0001654954-24-002898.md","text":"https://secwatch.observer/filing/0001654954-24-002898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1014763/000165495424002898/0001654954-24-002898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1014763/000165495424002898/aimd_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T00:21:07.652271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f892282e90eaeda4cc3532f5bc33c3a900679d7","claim":"Ainos, Inc. reported the year ended December 31, 2023 results: revenue US$122,112, net income US$13,770,549.","evidence_excerpt":"amount of US$3 million. These transactions provided us with additional capital as we implement our growth strategy.” Full Year 2023 Financial Results Revenues Revenues were US$122,112, compared to US$3,519,627 in the full year of 2022, reflecting a decrease in selling price and sales volume of the Company's COVID-19 Antigen Rapid Test Kits attributable to the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1014763/000165495424002898/0001654954-24-002898-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"US$122,112"},{"label":"Net income","value":"US$13,770,549"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}